Clinical Trial Detail

NCT ID NCT02818023
Title Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Pittsburgh
Indications

mucosal melanoma

skin melanoma

melanoma

Therapies

Cobimetinib + Pembrolizumab + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST